News & Updates
Filter by Specialty:
Serum osteopontin levels predicts response to treatment in unresectable HCC
Among patients with unresectable hepatocellular carcinoma (HCC) scheduled to receive standard combination therapy with atezolizumab plus bevacizumab, those with high levels of serum osteopontin at baseline are likely to have poor response to treatment, as shown in a study.
Serum osteopontin levels predicts response to treatment in unresectable HCC
25 May 2023
Paediatric TB care riddled with uncertainty, study says
Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.
Paediatric TB care riddled with uncertainty, study says
25 May 2023
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.
Sofosbuvir/velpatasvir effective, safe for paediatric HCV
25 May 2023
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains
25 May 2023
Higher vitamin D dose beneficial for paediatric obesity-related asthma
A 50,000-IU loading dose of oral vitamin D plus 8,000 IU daily is effective and safe for increasing serum 25(OH)D levels to ≥40 ng/mL in children and adolescents with asthma who were overweight or obese, as opposed to the standard of care (SoC) dose of 600 IU daily, according to findings from the VDORA1* trial.